

# Kluwer Patent Blog

## Decision finding that “Swiss claims” were affected by Spain’s Reservation to the EPC now revoked

Miquel Montaña (Clifford Chance) · Monday, June 18th, 2018

In July 2017, the Patents Court of Barcelona handed down a decision finding that “Swiss-type” claims were affected by the Reservation made by Spain when it ratified the European Patent Convention (“EPC”), whereby European patents, insofar as they confer protection on chemical or pharmaceutical products “*as such*”, shall be ineffective in Spain. In particular, the decision lifted a preliminary injunction that had been ordered “*ex parte*”, based on claim 16 of the patent asserted, and which read as follows:

*“Use according to claim 15, wherein the pharmaceutical composition is for treating hypercholesterolemia, hyperlipoproteinemia and atherosclerosis”.*

This decision caused an earthquake within Spanish patent circles for several reasons.

First, because of the clarity of the case law from the Supreme Court, which in many previous judgments had already rejected the proposition that “Swiss-type” claims were affected by Spain’s Reservation to the EPC. However, to be fair to the Court, it must be said that the judgment of 18 July 2013 from the Court of Justice of the European Union (“CJEU”), with regard to TRIPS and pharmaceutical patents in the *Daiichi* case, caused a lot of confusion among Spanish Courts. For a more elaborated discussion on the formidable paradoxes raised by that judgment readers will find an article by this author in *IIC – International Review of Intellectual Property and Competition Law* (2017) 48: 784-812. It is also fair to add that on 19 December 2016 the Court of Appeal of Barcelona (Section 15) had published a decision in another somewhat similar case (albeit dealing with EPC 2000 “product-limited-by-use” claims), which was probably less clear than it could have been.

The second reason why the decision shocked the patent community was because of the astronomical damages caused by the lifting of the preliminary injunction. In a scenario where prudence normally leans towards maintaining the status quo, this decision followed a different path.

Now all this is history. For in a decision dated 16 May 2018, the Court of Appeal of Barcelona (Section 15) revoked that controversial decision and reiterated that “Swiss-type” claims were not affected by Spain’s Reservation to the EPC. In spite of upholding the appeal, the Court of Appeal noted that the preliminary injunction could not be reinstated because the Supplementary Protection Certificate had already expired.

All in all, this case is a rather harsh and sad illustration of the astronomical damages that may be caused by the lifting of a preliminary injunction and the impossibility of effectively remedying a judicial error in cases where the intellectual property right asserted is subject to an expiry date, such as in the case of patents.

---

*To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please [subscribe here](#).*

## Kluwer IP Law


The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.

---

79% of the lawyers think that the importance of legal technology will increase for next year.

**Drive change with Kluwer IP Law.**  
The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT  
The Wolters Kluwer Future Ready Lawyer  
Leading change

This entry was posted on Monday, June 18th, 2018 at 6:42 pm and is filed under [Pharmaceutical patent](#), [Spain](#), [TRIPS](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.

